FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease - Aug 12, 2025

Insmed (Nasdaq: INSM) announced FDA approval for BRINSUPRI™ (brensocatib), the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB), a chronic and progressive lung disease affecting approximately 500,000 U.S. patients with no prior approved therapies. This first-in-class DPP1 inhibitor, which targets neutrophilic inflammation, demonstrated significant reductions in annual exacerbation rates in Phase 3 trials, potentially establishing a new standard of care. BRINSUPRI is now available in the U.S., with regulatory applications accepted in Europe and planned for Japan in 2025, positioning Insmed to address a substantial unmet medical need globally.

Analysis

Insmed (INSM) has secured a pivotal FDA approval for BRINSUPRI™ (brensocatib), establishing it as the first and only approved treatment for non-cystic fibrosis bronchiectasis (NCFB). This landmark approval positions the company to address a significant unmet medical need, targeting an estimated 500,000 diagnosed patients in the U.S. alone. The drug's first-in-class status as a DPP1 inhibitor, which directly targets the underlying neutrophilic inflammation, is supported by robust Phase 3 ASPEN trial data showing a statistically significant reduction in annual exacerbations of approximately 20% and a slowing of lung function decline. This strong clinical profile suggests BRINSUPRI could rapidly become the standard of care. Commercially, the drug is now available in the U.S. through a specialty pharmacy network, and the company has a clear global expansion strategy with regulatory applications already accepted in Europe and the UK and a filing planned for Japan in 2025, significantly expanding the total addressable market. While the safety profile appears manageable, with noted dermatologic and periodontal adverse reactions, the primary focus shifts to successful commercial execution, including pricing, reimbursement, and market penetration.

Key Decisions for Investors

• Given the first-in-class and first-to-market status in a therapeutic area with no approved treatments, investors should monitor initial U.S. launch metrics, including prescription volumes and payor coverage, which will be key indicators of commercial success.
• The defined global regulatory pathway, with filings accepted in Europe and planned for Japan, presents a medium-term growth catalyst, and valuation models should begin to incorporate potential revenue streams from these territories, anticipated to commence in 2026.
• While the efficacy data is compelling, it is prudent to track post-market surveillance data and physician feedback regarding the noted adverse reactions, as real-world safety and tolerability will be critical for long-term adoption and patient adherence.